Drugmaker Bets Big on Biopharma
A Chinese drugmaker plans to issue more than 1 billion yuan ($151.85 million) in bonds to build a new biopharmaceutical industrial park in the eastern city of Hangzhou.
The bond issuance makes Zhejiang Huahai Pharmaceutical Co. Ltd. just the latest of an army of biotech companies to invest big in biopharmaceutical research and development.
Huahai Pharmaceutical, whose major business is providing active ingredients for drugs to foreign and domestic pharmaceutical companies, announced it will issue 1.8 billion yuan in convertible bonds, 68% of which will be used to fund the biopharmaceutical park in Hangzhou, the capital of Zhejiang province.
The company will fund three other projects with the remainder.
In late 2011, the Ministry of Science and Technology projected the biology industry will grow 15% annually through to 2015. In January this year, China’s National Development and Reform Commission forecast that the output of China’s drug companies will hit 600 billion yuan by the end of the decade.
Following the political winds, venture capital funding in Chinese biopharma companies from 2012 to 2016 surged more than sixteenfold to more than $1 billion, according to BioCentury’s online intelligence service BCIQ.
In 2013, Huahai Pharmaceutical signed a partnership with U.S. biotech drugmaker Oncobiologics Inc. to secure the marketing rights for four drugs in China. The pair also planned to set up a joint venture in the U.S. for drug development.
However, the two companies have since scaled back the deal so that Huahai Pharmaceutical only has the rights to two drugs. The planned joint venture was also scrapped due to a “market change,” the Chinese company said in a filing to the Shanghai Stock Exchange in February 2016.
The Chinese drug supplier has shown a revived interest in biopharma this year. In May, it invested 36 million yuan in Chinese biopharma developer Hangzhou DAC Biotech Co. Ltd., and earlier this month it bought a stake in South Korean peer Eutilex Co. Ltd.
Contact reporter Coco Feng (email@example.com)
Jan 24 06:56
Jan 24 06:01
Jan 24 02:16
Jan 23 18:30
Jan 23 16:00
Jan 23 10:48
Jan 23 05:58
Jan 23 03:49
Jan 23 03:41
Jan 23 03:09
Jan 22 15:44
Jan 22 06:31
Jan 22 03:47
Jan 22 03:06
Jan 21 17:02
- 1Wuhan Virus Latest: Malaysia, Nepal, Australia, France Confirm First Cases of Infection
- 2Reporter’s Note: We Stayed in Wuhan as the Last Trains Pulled Out
- 3Wuhan Virus Update: Health Expert Warns of ‘Super-Spreader’ of Viral Pneumonia
- 4How Did Two Women Drive a Luxury SUV Into the Forbidden City?
- 5After Layoffs, Oracle Executive Vows to Stay in China
- 1Power To The People: Pintec Serves A Booming Consumer Class
- 2Largest hotel group in Europe accepts UnionPay
- 3UnionPay mobile QuickPass debuts in Hong Kong
- 4UnionPay International launches premium catering privilege U Dining Collection
- 5UnionPay International’s U Plan has covered over 1600 stores overseas